Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 4/20 | 0.41 |
| ▸ | MMP9 | P14780 | 12/20 | 0.40 |
| ▸ | MMP2 | P08253 | 12/20 | 0.39 |
| ▸ | MMP3 | P08254 | 11/20 | 0.39 |
| ▸ | MMP13 | P45452 | 11/20 | 0.39 |
| ▸ | MMP1 | P03956 | 10/20 | 0.39 |
| ▸ | MMP7 | P09237 | 10/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13978713 | 0.83 | ADAMTS4 (0.47) | ADAMTS4MMP9MMP2MMP13GAA | |
| SCHEMBL3615326 | 0.78 | MMP2 (0.61) | ADAMTS4MMP9MMP2MMP3MMP13 | |
| SCHEMBL14176097 | 0.78 | MMP9 (0.47) | ADAMTS4MMP9MMP2MMP3MMP13 | |
| SCHEMBL1656896 | 0.78 | MMP2 (0.61) | ADAMTS4MMP9MMP2MMP3MMP13 | |
| SCHEMBL8283236 | 0.78 | MMP2 (0.61) | ADAMTS4MMP9MMP2MMP3MMP13 | |
| SCHEMBL14419201 | 0.77 | MMP9 (0.56) | ADAMTS4MMP9MMP2MMP3MMP13 | |
| SCHEMBL10208755 | 0.77 | ADAMTS4 (0.54) | ADAMTS4MMP9MMP2MMP3MMP13 | |
| SCHEMBL10209982 | 0.77 | ADAMTS4 (0.54) | ADAMTS4MMP9MMP2MMP3MMP13 | |
| SCHEMBL7087648 | 0.77 | MMP9 (0.64) | ADAMTS4MMP9MMP2MMP3MMP13 | |
| SCHEMBL5093836 | 0.77 | MMP9 (0.64) | ADAMTS4MMP9MMP2MMP3MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923446-B2 | 3-Methyl-2-[4'-(pyridin-3-ylmethoxymethyl)-biphenyl-4-sulfonylamino]-butyric acid; metalloproteinase inhibitors; arthritis, macular degeneration, graft versus host disease, cancer, osteoarthritis | WYETH LLC (US) | 2011-04-12 | — | — | US | disclosed |
| EP-1689380-A4 | METHOD FOR TREATING ADAMTS-5-ASSOCIATED DISEASE | WYETH CORP (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20080311113-A1 | METHOD FOR TREATING ADAMTS-5-ASSOCIATED DISEASE | WYETH (US) | 2008-12-18 | — | — | US | disclosed |
| US-7390833-B2 | Method for treating ADAMTS-5-associated disease | WYETH (US) | 2008-06-24 | — | — | US | disclosed |
| US-20070225327-A1 | Biaryl Sulfonamides and Methods for Using Same | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7268135-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1689380-A2 | METHOD FOR TREATING ADAMTS-5-ASSOCIATED DISEASE | Wyeth (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1689716-A1 | BIARYL SULFONAMIDES AND METHODS FOR USING SAME | Wyeth (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20060004066-A1 | Method for treating ADAMTS-5-associated disease | WYETH (US) | 2006-01-05 | — | — | US | disclosed |
| WO-2005060456-A2 | METHOD FOR TREATING ADAMTS-5-ASSOCIATE DISEASE | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005061459-A1 | BIARYL SULFONAMIDES AND METHODS FOR USING SAME | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050130973-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130973-A1 | Biaryl sulfonamides and methods for using same | STS, MMP3, AADAC | ADAMTS4 113/4885MMP9 14/4885MMP2 5/4885 |
| US-20060004066-A1 | Method for treating ADAMTS-5-associated disease | ADAMTS5, ADAMTS1, ADAMTS4 | ADAMTS4 3/4885MMP9 87/4885MMP2 119/4885 |
| US-20080311113-A1 | METHOD FOR TREATING ADAMTS-5-ASSOCIATED DISEASE | ADAMTS5, ADAMTS1, ADAMTS4 | ADAMTS4 3/4885MMP9 87/4885MMP2 119/4885 |
| US-20070225327-A1 | Biaryl Sulfonamides and Methods for Using Same | STS, MMP3, AADAC | ADAMTS4 113/4885MMP9 14/4885MMP2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.